Wisconsin Capital Management LLC Invests $220,000 in Abbott Laboratories (NYSE:ABT)

Wisconsin Capital Management LLC acquired a new position in Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,000 shares of the healthcare product maker’s stock, valued at approximately $220,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Stevens Capital Management LP boosted its stake in shares of Abbott Laboratories by 130.6% in the 4th quarter. Stevens Capital Management LP now owns 10,502 shares of the healthcare product maker’s stock valued at $1,156,000 after purchasing an additional 5,948 shares in the last quarter. Syon Capital LLC grew its holdings in Abbott Laboratories by 97.0% during the 4th quarter. Syon Capital LLC now owns 17,099 shares of the healthcare product maker’s stock worth $1,882,000 after acquiring an additional 8,421 shares during the last quarter. Meritage Portfolio Management increased its position in Abbott Laboratories by 30.3% in the 4th quarter. Meritage Portfolio Management now owns 3,916 shares of the healthcare product maker’s stock valued at $431,000 after acquiring an additional 910 shares in the last quarter. Disciplined Equity Management Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $55,000. Finally, GHE LLC grew its stake in shares of Abbott Laboratories by 1.5% during the fourth quarter. GHE LLC now owns 12,547 shares of the healthcare product maker’s stock valued at $1,381,000 after purchasing an additional 182 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Andrea F. Wainer sold 42,500 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, EVP Andrea F. Wainer sold 42,500 shares of Abbott Laboratories stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,435 shares of company stock valued at $6,451,298. Company insiders own 1.10% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT remained flat at $106.89 during mid-day trading on Thursday. 3,111,313 shares of the company were exchanged, compared to its average volume of 5,687,034. The company has a market cap of $185.47 billion, a price-to-earnings ratio of 33.30, a PEG ratio of 2.59 and a beta of 0.74. The stock has a fifty day moving average of $113.77 and a 200 day moving average of $107.96. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The business had revenue of $9.96 billion during the quarter, compared to analysts’ expectations of $9.88 billion. During the same quarter in the prior year, the company earned $1.03 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. On average, equities analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.06%. Abbott Laboratories’s payout ratio is 68.54%.

Analyst Ratings Changes

Several research firms recently weighed in on ABT. Raymond James restated a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research report on Wednesday. Citigroup upped their price target on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada decreased their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, April 18th. Evercore ISI boosted their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Barclays reduced their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $121.50.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.